Unraveling tumor heterogeneity in prostate cancer by combined immunohistochemistry and RNA in situ hybridization

2016 ◽  
Vol 07 (04) ◽  
Author(s):  
Nallasivam Palanisamy
2016 ◽  
Vol 22 (18) ◽  
pp. 4651-4663 ◽  
Author(s):  
Liana B. Guedes ◽  
Carlos L. Morais ◽  
Fawaz Almutairi ◽  
Michael C. Haffner ◽  
Qizhi Zheng ◽  
...  

2019 ◽  
Vol 48 (3) ◽  
pp. e17-e17 ◽  
Author(s):  
Lena Voith von Voithenberg ◽  
Anna Fomitcheva Khartchenko ◽  
Deborah Huber ◽  
Peter Schraml ◽  
Govind V Kaigala

Abstract Multiplexed RNA in situ hybridization for the analysis of gene expression patterns plays an important role in investigating development and disease. Here, we present a method for multiplexed RNA-ISH to detect spatial tumor heterogeneity in tissue sections. We made use of a microfluidic chip to deliver ISH-probes locally to regions of a few hundred micrometers over time periods of tens of minutes. This spatial multiplexing method can be combined with ISH-approaches based on signal amplification, with bright field detection and with the commonly used format of formalin-fixed paraffin-embedded tissue sections. By using this method, we analyzed the expression of HER2 with internal positive and negative controls (ActB, dapB) as well as predictive biomarker panels (ER, PgR, HER2) in a spatially multiplexed manner on single mammary carcinoma sections. We further demonstrated the applicability of the technique for subtype differentiation in breast cancer. Local analysis of HER2 revealed medium to high spatial heterogeneity of gene expression (Cohen effect size r = 0.4) in equivocally tested tumor tissues. Thereby, we exemplify the importance of using such a complementary approach for the analysis of spatial heterogeneity, in particular for equivocally tested tumor samples. As the method is compatible with a range of ISH approaches and tissue samples, it has the potential to find broad applicability in the context of molecular analysis of human diseases.


Author(s):  
Jillian N. Eskra ◽  
Daniel Rabizadeh ◽  
Leslie Mangold ◽  
Elizabeth Fabian ◽  
W. Nathaniel Brennen ◽  
...  

2020 ◽  
Vol 33 (9) ◽  
pp. 1791-1801 ◽  
Author(s):  
Pavithra Dedigama-Arachchige ◽  
Shannon Carskadon ◽  
Jia Li ◽  
Ian Loveless ◽  
Mohamed Alhamar ◽  
...  

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 191-191
Author(s):  
Yezi Zhu ◽  
Adam Sharp ◽  
Courtney M Anderson ◽  
John Silberstein ◽  
Maritza N. Taylor ◽  
...  

191 Background: Previous studies have reported an association between blood-based detection of androgen receptor splice variant-7 (AR-V7) and resistance to abiraterone/enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC). Further characterization of AR-V7 and its clinical correlates are necessary but depend on the development of methods that allow for reliable and specific measurement of AR-V7. In this study, we developed and evaluated a novel junction-specific AR-V7 RNA in situ hybridization (RISH) test. Methods: We developed a novel RISH assay targeting single exon-exon junction, allowing for highly-specific detection of mature cytoplasmic AR-FL and AR-V7 mRNA in native cell and tissue environment. We compared quantitative RISH AR-V7 results generated from an automated scoring system with AR-V7 levels quantified by RT-PCR in a panel of cell lines. Using the validated assay, we quantified AR-V7 signals in 58 prostate tumor biopsies. We conducted preliminary evaluation of the clinical correlates of AR-V7 detected. Results: The novel AR-V7 RISH test specifically detected mature cytoplasmic AR-V7 mRNA and did not detect nuclear pre-mRNA. AR-V7 RISH results were highly concordant with RT-PCR results. We generated quantitative AR-FL and AR-V7 data from 93.1% of the clinical specimens examined (54 of 58). Positive AR-V7 signals were detected in 23 specimens, all of which also co-expressed AR-FL. The median AR-V7/AR-FL ratio was 4.6%. Positive detection of AR-V7 was significantly correlated with prior treatment with second-line AR targeting agents and serum PSA ( p <0.05), but not with any other baseline clinical variables. Notably, all castration-sensitive prostate cancer specimens (CSPC) (n = 9) were AR-V7 negative by this method. Association between AR-V7 and treatment outcome has yet to be fully evaluated. Conclusions: We demonstrate for the first time a highly specific and quantifiable AR-V7 RISH test for detection of clinically significant levels of AR-V7 mRNA in prostate tissue specimens. This test may be applied to liquid biopsy specimens to expand the utility. Prospective studies can be designed to evaluate the potential utility of this novel test in drug development and patient management.


2013 ◽  
Vol 27 (4) ◽  
pp. 609-620 ◽  
Author(s):  
Joshua I Warrick ◽  
Scott A Tomlins ◽  
Shannon L Carskadon ◽  
Allison M Young ◽  
Javed Siddiqui ◽  
...  

Author(s):  
Jillian N. Eskra ◽  
Daniel Rabizadeh ◽  
Jiayi Zhang ◽  
William B. Isaacs ◽  
Jun Luo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document